StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly jardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M) ($M)

Form 10-Q / 10-K Note 2 & MD&A

QuarterlyAnnual
Latest, FY2025
3,432
Period ended Dec 31, 2025
Change on a year earlier
+2.7%
3,341 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedJardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M) ($M)Year on yearSource
FY2025Dec 31, 20253,432+2.7%Form 10-K (filed 2026-02-12) ↗
FY2024Dec 31, 20243,341+21.7%Form 10-K (filed 2026-02-12) ↗
FY2023Dec 31, 20232,745+32.9%Form 10-K (filed 2026-02-12) ↗
FY2022Dec 31, 20222,066+38.6%Form 10-K (filed 2025-02-19) ↗
FY2021Dec 31, 20211,491+29.2%Form 10-K (filed 2024-02-21) ↗
FY2020Dec 31, 20201,154+22.2%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 2019944+43.4%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 2018658+47.1%Form 10-K (filed 2021-02-17) ↗
FY2017Dec 31, 2017448+121.6%Form 10-K (filed 2020-02-19) ↗
FY2016Dec 31, 2016202–Form 10-K (filed 2019-02-19) ↗

Breakdown

What makes up jardiance (empagliflozin, incl. glyxambi, synjardy & trijardy xr) — worldwide revenue ($m)

Cite this data

StockData. (2026). Eli Lilly Jardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_jardiance_ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.